Progressive Familial Intrahepatic Cholestasis

Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases

Ipsen and Albireo announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases. The anticipated acquisition will enrich Ipsen’s Rare Disease portfolio and pipeline. The lead medicine in Albireo’s pipeline...